Ligand Pharmaceuticals Current Ratio 2006-2021 | LGND

Ligand Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Ligand Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.41B $0.05B 7.83
2021-03-31 $0.44B $0.10B 4.57
2020-12-31 $0.50B $0.10B 5.00
2020-09-30 $0.86B $0.04B 20.28
2020-06-30 $0.86B $0.03B 29.51
2020-03-31 $0.83B $0.02B 40.65
2019-12-31 $1.12B $0.02B 66.09
2019-09-30 $1.18B $0.04B 33.15
2019-06-30 $1.44B $0.11B 13.23
2019-03-31 $1.57B $0.19B 8.39
2018-12-31 $0.87B $0.08B 10.58
2018-09-30 $1.75B $0.79B 2.20
2018-06-30 $1.48B $0.63B 2.34
2018-03-31 $0.35B $0.25B 1.41
2017-12-31 $0.24B $0.24B 0.99
2017-09-30 $0.22B $0.23B 0.97
2017-06-30 $0.20B $0.23B 0.87
2017-03-31 $0.18B $0.23B 0.77
2016-12-31 $0.16B $0.23B 0.72
2016-09-30 $0.14B $0.23B 0.62
2016-06-30 $0.13B $0.22B 0.57
2016-03-31 $0.13B $0.01B 10.87
2015-12-31 $0.22B $0.22B 0.96
2015-09-30 $0.21B $0.02B 12.94
2015-06-30 $0.20B $0.02B 10.96
2015-03-31 $0.19B $0.02B 10.56
2014-12-31 $0.19B $0.02B 8.13
2014-09-30 $0.20B $0.02B 10.77
2014-06-30 $0.03B $0.02B 1.54
2014-03-31 $0.03B $0.02B 1.59
2013-12-31 $0.03B $0.03B 0.86
2013-09-30 $0.02B $0.03B 0.51
2013-06-30 $0.02B $0.03B 0.45
2013-03-31 $0.02B $0.03B 0.54
2012-12-31 $0.02B $0.04B 0.67
2012-09-30 $0.02B $0.03B 0.58
2012-06-30 $0.02B $0.03B 0.68
2012-03-31 $0.02B $0.03B 0.87
2011-12-31 $0.03B $0.04B 0.74
2011-09-30 $0.03B $0.04B 0.63
2011-06-30 $0.03B $0.04B 0.67
2011-03-31 $0.03B $0.05B 0.70
2010-12-31 $0.04B $0.03B 1.11
2010-09-30 $0.04B $0.04B 0.96
2010-06-30 $0.04B $0.04B 1.00
2010-03-31 $0.05B $0.04B 1.22
2009-12-31 $0.07B $0.05B 1.31
2009-09-30 $0.06B $0.05B 1.13
2009-06-30 $0.07B $0.05B 1.44
2009-03-31 $0.07B $0.05B 1.28
2008-12-31 $0.09B $0.07B 1.33
2008-09-30 $0.09B $0.05B 1.66
2008-06-30 $0.10B $0.05B 2.15
2008-03-31 $0.10B $0.04B 2.30
2007-12-31 $0.11B $0.05B 2.16
2007-09-30 $0.12B $0.06B 1.94
2007-06-30 $0.13B $0.07B 1.94
2007-03-31 $0.43B $0.34B 1.26
2006-12-31 $0.24B $0.17B 1.38
2006-09-30 $0.07B $0.23B 0.29
2006-06-30 $0.11B $0.27B 0.42
2006-03-31 $0.11B $0.26B 0.44
2005-12-31 $0.13B $0.24B 0.57
2005-09-30 $0.12B $0.23B 0.52
2005-06-30 $0.11B $0.21B 0.51
2005-03-31 $0.13B $0.22B 0.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.273B $0.186B
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76